Navigation Links
Agility Clinical Partners with PSR Orphan Drug Experts

CARLSBAD, Calif., March 5, 2013 /PRNewswire/ -- Agility Clinical, Inc., a specialty consulting and clinical research organization, has partnered with PSR Orphan Experts, a European orphan drug specialty consulting and clinical research company, based in the Netherlands, a move that will provide clients with access to orphan drug development expertise and services on both sides of the Atlantic. The term "orphan drug" refers to pharmaceutical products developed specifically to treat rare diseases. A rare disease is one that affects fewer than 200,000 Americans or less than one in 2,000 Europeans.

Carlsbad-based Agility Clinical and Netherlands-based PSR specialize in orphan drug development, helping pre-clinical and clinical stage companies, by providing strategic and operational consulting support, in addition to traditional CRO services. Both firms specialize in developing complex clinical development programs that require innovative regulatory and clinical development approaches.

"We're excited to mutually benefit from the collaboration and expertise of the two firms, and see a growing need in this important area," says Ellen Morgan , Agility CEO and 30-year industry veteran. "With few CROs focused on rare diseases, partnering with another like company to share knowledge and experiences strengthens our services to clients, and our reach." Prior to joining Agility, Morgan co-founded and was CEO and chairman of a California-based CRO that grew to over 300 employees and provided clinical services to hundreds of companies during her tenure.

"Given the current challenges in orphan drug development, it is of crucial importance to provide innovative & solid infrastructure and expert services," says Roger Legtenberg, CEO of PSR Orphan Experts. "By further strengthening the geographical reach for both companies to both sides of the Atlantic, we are able to provide an efficient clinical drug development strategy to our clients."

The number of rare diseases for which no treatment is currently available is estimated at approximately 6,800, according to the National Institute of Health (NIH). Nearly 30 million Americans, almost 1 in 10, are affected by a rare disease. Orphan drugs present fundamentally different regulatory and operational challenges than their traditional drug counterparts. Agility and PSR both specialize in helping companies develop efficiencies and economies of scale to help patients with rare diseases by bringing innovative new drugs and devices to market.

About Agility Clinical
Agility Clinical, founded in April 2012, with an experienced executive management team whose mission is to help small and virtual pre-clinical and clinical stage companies develop drugs and devices, particularly in the orphan drug category. In addition to consulting, Agility provides customized full clinical trial services including project management, clinical operations, data management, biostatistics, medical, regulatory, and scientific affairs, medical writing and electronic source records (ESR). The Agility team has a true appreciation for the challenges its clients face in obtaining the expertise they need. The firm's senior staff volunteers time with its partner, the Public Health Alliance for Clinical Trials (PHACT), the first non-profit CRO dedicated to conducting clinical trials for products to treat diseases that affect the poorest people in developing countries. Agility has established operations in Carlsbad, CA. For more information, visit and

About PSR Orphan Experts
PSR Group B.V., established in 1998, is a leading expert in orphan drug development in Europe. PSR assists companies to design and execute successful clinical development strategies for orphan indications, thereby specializing in complex clinical development programs requiring innovative regulatory and clinical approaches. PSR's services range from regulatory & clinical consultancy to full clinical research services (project management, monitoring, regulatory affairs, electronic data capture/data management and statistics/medical writing). For more information, please visit

Contact: Amy Zimmerman
A.Z. Communications

SOURCE Agility Clinical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Quebec Clinic Launches Canadian Use of Elektas Agility Beam-Shaping Innovation for Radiation Therapy of Cancer
2. Agility Clinical Expands Consulting Services to More Broadly Serve Small and Virtual Biopharma and Device Companies
3. Elekta to Showcase Revolutionary Agility Beam-shaping Innovation at Radiation Physics Annual Meeting
4. Austrian Medical Center Upgrades Cancer Treatment System, Improves Patient Care with Elektas Agility Beam-shaping Device
5. Pharma Clinical Trial Services: World Market 2013-2023
6. Synteract und Harrison Clinical Research vereinbaren die Gründung eines multinationalen Auftragsforschungsinstituts
7. Synteract and Harrison Clinical Research Close Deal to Form Multinational CRO
8. Citiustech Announces Launch of Bi-Clinical Cloud and App-Based Architecture
9. Elsevier Showcases Predictive Analytic and Clinical Integration Solutions at HIMSS13
10. Spring Bank Pharmaceuticals Closes $10.5 million Series A Financing to fund Phase I Clinical Trials in HCV-infected Patients
11. Independent Study Published in Clinical Infectious Diseases Highlights the Importance of Antimicrobial Removal Systems in Blood Culture to Rapidly and Accurately Aid in the Diagnosis of Sepsis
Post Your Comments:
(Date:11/30/2015)...  QT Vascular Ltd., together with its subsidiaries (the ... TriReme Medical LLC and Quattro Vascular Pte. Ltd., collectively ... assembly and distribution of advanced therapeutic solutions for the ... announce that a three-judge panel of the ... Federal Circuit ("Federal Circuit") has unanimously granted the Group ...
(Date:11/30/2015)... ) has ... Market 2015-2019" report to their offering. ... of the "Orphan Drugs Market 2015-2019" ... and Markets ( ) has announced the ... report to their offering. ...
(Date:11/30/2015)... -- IBA Molecular North America, Inc. (IBAMNA), a U.S. leader ... as of January 1, 2016, it will do business ... rebrand the company reflects a refined vision for the ... relationship with Zevacor Molecular.  Both IBAMNA and Zevacor Molecular ... Peter Burke , Vice President Sales and ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani as ... Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center marketplace. ...
(Date:11/30/2015)... ... ... Trevor and Taylor Crabb have unveiled an exciting new campaign to unite ... States. This hybrid crowdfunding campaign is designed to provide the Crabb brothers’ ... offering corporate sponsors with some great marketing deliverables with the brothers for the 2016 ...
(Date:11/30/2015)... ... ... The National Association of Professional Women (NAPW) honors Dawn ... She is recognized with this prestigious distinction for leadership in estate sales and moving. ... 850,000 members and over 200 operating Local Chapters. , “I’m pleased to welcome Dawn ...
(Date:11/30/2015)... ... December 01, 2015 , ... ... to offer individual vision insurance plans on . The multi-carrier insurance ... rate and review products, allowing consumers to compare, quote and match plans to ...
(Date:11/30/2015)... ... November 30, 2015 , ... During the National ... caregivers and held two webinars on topics of ‘Medical and Palliative Care Decisions,’ ... at . , With a loved one's diagnosis of mesothelioma, the ...
Breaking Medicine News(10 mins):